StockDrifts LogoStockDrifts

Well Biotech 010600

Company
웰바이오텍Well Biotech
Insiders
1
Buys
5
Total Value
₩144M ($100K)
Avg Return
-22.93%
Last Filing
2026-01-27

Well Biotech (010600) has 5 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩144M ($100K) in reported transaction value. The earliest filing StockDrifts holds for Well Biotech is dated 2026-01-21; the most recent is 2026-01-27. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -22.93%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-01-27BUYMarket Buy
김한국
Kim Korea
CEO7.0M---
2026-01-26BUYMarket Buy
김한국
Kim Korea
CEO7.6M---
2026-01-23BUYMarket Buy
김한국
Kim Korea
CEO3.1M₩11+0.0%₩34M ($24K)
2026-01-22BUYMarket Buy
김한국
Kim Korea
CEO2.3M₩15-26.7%₩34M ($24K)
2026-01-21BUYMarket Buy
김한국
Kim Korea
CEO4.0M₩19-42.1%₩76M ($53K)

Frequently asked questions

Who has been buying Well Biotech stock?
1 distinct insiders have filed 5 disclosed insider purchases in Well Biotech (010600), most recently on 2026-01-27. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Well Biotech have?
Well Biotech has 5 buy-side and 0 sell-side disclosures on record, covering ₩144M ($100K) in total reported value, spanning 2026-01-21 to 2026-01-27.
Where does StockDrifts get Well Biotech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Well Biotech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.